News
Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer;
Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry (IHC) score of 0 or 1+ using standard HER2 assays, according to findings from an analysis presented during the 2021 San Antonio Breast Cancer Symposium. “The scoring accuracy for HER2 IHC in the low range [0 and 1+] is poor,” says lead study author Aileen Fernandez, PhD, of Yale Department of Pathology. “This inaccuracy in the real world could lead to mis-assignment of many patients for treatment with fam-trastuzumab deruxtecan-nxki [Enhertu] for [those who are] HER2 low.”
Source: OncLive.com